<DOC>
	<DOCNO>NCT00411645</DOCNO>
	<brief_summary>The purpose research study investigate whether maribavir safe effective prevent CMV disease take mouth 12 week patient stem cell transplant .</brief_summary>
	<brief_title>Prophylactic Use Maribavir Prevention Cytomegalovirus ( CMV ) Disease Stem Cell Transplant Recipients</brief_title>
	<detailed_description>Cytomegalovirus ( CMV ) infection remain significant problem follow various type transplant associate strong immunosuppressive therapy . Maribavir new oral anti-CMV drug novel mechanism action compare currently available anti-CMV drug . This study test safety efficacy maribavir prevention CMV disease give prophylaxis 12 week follow allogeneic stem cell transplant .</detailed_description>
	<mesh_term>Cytomegalovirus Infections</mesh_term>
	<criteria>Allogeneic stem cell transplant recipient Recipient donor CMV seropositive Have transplant engraftment Able swallow tablet CMV organ disease HIV infection Use antiCMV therapy posttransplant</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2014</verification_date>
	<keyword>prevention</keyword>
	<keyword>prophylaxis</keyword>
	<keyword>Cytomegalovirus</keyword>
	<keyword>CMV</keyword>
	<keyword>allogeneic stem cell transplant</keyword>
	<keyword>SCT</keyword>
</DOC>